Prostate Cancer Therapeutics Market, by Drug Type (Hormonal Therapy, Anti-androgens, Immunotherapy, Targeted Therapy, and Chemotherapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and by Geography - Global Trends, and Forecast to 2025

Published In : Jan 2018

Code : CMI1257

Pages :160

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges And Opportunities

However, high cost associated with drugs, and poor reimbursement of treatment cost may affect the prostate cancer therapeutics negatively.

Endeavor to introduce highly effective therapies for prostate cancer would support the market growth

Many research organizations and universities are investing in research for the development of therapeutic products for the treatment of such tumors. For instance, some pipeline products which are in phase 2 studies, such as Avelumab (Duke University Medical Center), Metformin (Mansoura University), LY2452473 (Dana-Farber Cancer Institute) are expected to arrive in the market in the near future. Furthermore, many products that are about to face patent expiry during the forecast period will also contribute in the growth of the generic prostate cancer therapeutics market. Many pharmaceutical companies are also focusing on introducing their respective drugs in different countries to boost the sales of their products. For instance, in December, 2016, Sanofi’s prostate cancer drug name Jevtana (cabazitaxel) for the treatment of metastatic hormone-refractory prostate cancer (mHRPC) was approved by Scottish Medicines Consortium (SMC) for restricted use within NHS Scotland, due to which Scotland has now collaborated with health authorities in Northern Ireland, England and Wales. Thereby, reducing potential disparities in care across the UK for this vulnerable group of patients.